PAVM

$10.39

Post-MarketAs of Mar 17, 8:00 PM UTC

PAVmed Inc.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$10.39
Potential Upside
5%
Whystock Fair Value$10.91
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for u...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.57M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.88
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
17.44%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.32

Recent News

GuruFocus.com
Nov 13, 2025

PAVmed Inc (PAVM) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Financial ...

PAVmed Inc (PAVM) reports significant strides in debt restructuring, strategic partnerships, and technology innovation, despite facing ongoing financial challenges.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Oct 10, 2025

PAVmed (PAVM) Upgraded to Strong Buy: Here's Why

PAVmed (PAVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Medical Device Network
Aug 28, 2025

PAVmed plans to license Duke’s oesophageal imaging technology

A PAVmed subsidiary seeks to obtain exclusive worldwide licensing rights for Duke University’s a/LCI + OCT technology.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
TipRanks
Jun 4, 2025

PAVmed subsidiary Veris Health partners with Ohio State University cancer center

PAVmed’s (PAVM) majority-owned digital health subsidiary Veris Health has entered into a strategic partnership agreement with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, or OSUCCC – James, a National Cancer Institute-Designated Comprehensive Cancer Center. This agreement follows the successful completion of a pilot program which enrolled patients across several OSUCCC – James cancer care service lines on the Ve

BEARISH
Negative press. News cycle fixated on risk factors or misses.
GuruFocus.com
May 16, 2025

PAVmed Inc (PAVM) Q1 2025 Earnings Call Highlights: Strategic Expansion and Financial Fortification

PAVmed Inc (PAVM) strengthens its financial position and explores new opportunities in biopharma amidst ongoing challenges.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.